My friend Alex Reid just might have created my favorite strategy right now. You see, Alex has figured out how to cut-the-corner so to speak, and be one of the laziest traders possible…. While still showing his traders how to target big money. This past year, his LIVE “lazy trade” alerts have delivered impressive results—and that’s only a fraction of the opportunities he’s shared. And that’s just just a quarter of the total trade alerts he’s sent out. The true total profit potential his beta-testers have had the chance to target is far larger than $20k.

Alex recorded a special video training where he reveals exactly how much.

ALLO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 24.30%

Insider Buying (Last 12 Months): $5,000,681.30

Insider Selling (Last 12 Months): $66,041.84

Allogene Therapeutics Insider Trading History Chart

Allogene Therapeutics Share Price & Price History

^$2.17

▲ +0.08 (3.83%)

As of 12/26/2024 06:36 PM ET

Days: 30 | 90 | 365

70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!

From WealthPress | Ad

Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.

>> You can grab your FREE, laminated copies right here <<

Allogene Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/9/2024	Deborah M Messemer	Director	Sell	9,136	$2.18	$19,916.48	157,629
12/5/2024	Franz B Humer	Director	Sell	9,221	$2.16	$19,917.36	307,507
5/30/2024	Franz B Humer	Director	Sell	11,200	$2.34	$26,208.00	255,253
5/16/2024	Arie Belldegrun	Director	Buy	1,724,137	$2.90	$4,999,997.30	1,724,137
1/30/2024	Geoffrey M Parker	CFO	Buy	190	$3.60	$684.00	819,590
12/18/2023	Deborah M Messemer	Director	Sell	18,640	$2.70	$50,328.00	62,456
8/7/2023	Stephen Mayo	Director	Sell	10,000	$4.29	$42,900.00	25,328
2/13/2023	Veer Bhavnagri	General Counsel	Sell	3,000	$6.85	$20,550.00	577,677
1/17/2023	Veer Bhavnagri	General Counsel	Sell	3,000	$7.04	$21,120.00	580,677
12/15/2022	Veer Bhavnagri	General Counsel	Sell	5,602	$7.53	$42,183.06	583,677
8/11/2022	Owen N. Witte	Director	Sell	10,000	$16.50	$165,000.00	223,271
8/2/2022	Rafael Amado	CMO	Sell	2,000	$11.97	$23,940.00	540,257
7/5/2022	Rafael Amado	CMO	Sell	2,000	$11.44	$22,880.00	542,257
6/22/2022	Owen N. Witte	Director	Sell	10,000	$11.76	$117,600.00	233,271
6/21/2022	Rafael Amado	CMO	Sell	2,000	$11.18	$22,360.00	544,257
5/19/2022	Rafael Amado	CMO	Sell	11,500	$7.40	$85,100.00	546,257
3/15/2022	Alison Moore	Insider	Sell	8,698	$7.63	$66,365.74
3/15/2022	David D Chang	CEO	Sell	23,648	$7.65	$180,907.20
3/15/2022	Eric Thomas Schmidt	CFO	Sell	11,469	$7.63	$87,508.47
3/15/2022	Rafael Amado	CMO	Sell	5,169	$7.71	$39,852.99
3/15/2022	Veer Bhavnagri	General Counsel	Sell	8,849	$7.68	$67,960.32
1/12/2022	Arie Belldegrun	Director	Buy	155,039	$12.60	$1,953,491.40

Has Trump Finally Gone Too Far?

From Insiders Exposed | Ad

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

SEC Filings (Institutional Ownership Changes) for Allogene Therapeutics (NASDAQ:ALLO)

83.63% of Allogene Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Allogene Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
12/26/2024	JPMorgan Chase & Co.	4,087,506	$11.45M	0.0%	-0.9%	1.949%
11/25/2024	Tidal Investments LLC	142,747	$0.40M	0.0%	-39.7%	0.068%
11/19/2024	Barclays PLC	342,973	$0.96M	0.0%	+101.5%	0.164%
11/16/2024	Geode Capital Management LLC	3,227,104	$9.04M	0.0%	+14.4%	1.539%
11/15/2024	Barclays PLC	342,973	$0.96M	0.0%	+101.5%	0.164%
11/15/2024	MML Investors Services LLC	20,000	$56K	0.0%	N/A	0.010%
11/15/2024	Zacks Investment Management	516,601	$1.45M	0.0%	N/A	0.246%
11/15/2024	EP Wealth Advisors LLC	24,475	$69K	0.0%	+125.6%	0.012%
11/15/2024	State Street Corp	7,013,083	$19.64M	0.0%	-8.5%	3.345%
11/15/2024	Erste Asset Management GmbH	31,400	$91K	0.0%	N/A	0.015%
11/14/2024	Vestal Point Capital LP	1,500,000	$4.20M	0.3%	-31.8%	0.715%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	228,806	$0.64M	0.0%	-14.2%	0.109%
11/14/2024	MetLife Investment Management LLC	53,147	$0.15M	0.0%	-10.1%	0.025%
11/13/2024	BNP Paribas Financial Markets	46,374	$0.13M	0.0%	+541.5%	0.022%
11/13/2024	FMR LLC	30,026,956	$84.08M	0.0%	-3.9%	14.321%
11/13/2024	The Manufacturers Life Insurance Company	486,023	$1.36M	0.0%	+1.2%	0.232%
11/9/2024	Intech Investment Management LLC	41,331	$0.12M	0.0%	N/A	0.020%
11/6/2024	Cornercap Investment Counsel Inc.	28,533	$80K	0.0%	-55.0%	0.014%
11/6/2024	Curi RMB Capital LLC	149,577	$0.42M	0.0%	+47.5%	0.072%
10/25/2024	China Universal Asset Management Co. Ltd.	40,219	$0.11M	0.0%	+64.0%	0.019%
10/22/2024	Private Advisor Group LLC	12,087	$34K	0.0%	N/A	0.006%
10/11/2024	Creative Planning	61,396	$0.17M	0.0%	+108.7%	0.029%
10/10/2024	Exchange Traded Concepts LLC	60,675	$0.17M	0.0%	+25.5%	0.029%
10/3/2024	SG Americas Securities LLC	46,967	$0.13M	0.0%	+252.7%	0.022%
8/16/2024	Perceptive Advisors LLC	2,725,000	$6.35M	0.2%	N/A	1.304%
8/16/2024	Algert Global LLC	14,808	$35K	0.0%	N/A	0.007%
8/15/2024	Susquehanna Fundamental Investments LLC	418,699	$0.98M	0.0%	+46.2%	0.200%
8/15/2024	Lynx1 Capital Management LP	2,228,295	$5.19M	1.9%	N/A	1.066%
8/15/2024	The Manufacturers Life Insurance Company	480,381	$1.12M	0.0%	+70.3%	0.230%
8/15/2024	AQR Capital Management LLC	27,287	$64K	0.0%	N/A	0.013%
8/15/2024	Caxton Associates LP	466,110	$1.09M	0.0%	+8.1%	0.223%
8/14/2024	Squarepoint Ops LLC	126,628	$0.30M	0.0%	N/A	0.061%
8/14/2024	Profund Advisors LLC	76,160	$0.18M	0.0%	-37.1%	0.036%
8/12/2024	Hsbc Holdings PLC	44,664	$0.10M	0.0%	-17.5%	0.021%
8/12/2024	E Fund Management Co. Ltd.	25,333	$59K	0.0%	-31.8%	0.012%
8/9/2024	Primecap Management Co. CA	5,670,226	$13.21M	0.0%	+4.1%	2.713%
8/9/2024	Renaissance Technologies LLC	1,747,955	$4.07M	0.0%	+340.4%	0.836%
8/9/2024	Dimensional Fund Advisors LP	2,550,640	$5.94M	0.0%	+24.8%	1.220%
8/8/2024	Federated Hermes Inc.	12,300	$29K	0.0%	N/A	0.006%
8/8/2024	American Century Companies Inc.	163,539	$0.38M	0.0%	+31.8%	0.078%
8/7/2024	Daiwa Securities Group Inc.	26,360	$61K	0.0%	-13.7%	0.013%
8/6/2024	Los Angeles Capital Management LLC	125,030	$0.29M	0.0%	-22.2%	0.060%
8/5/2024	Arizona State Retirement System	40,915	$95K	0.0%	+36.1%	0.020%
8/3/2024	TD Asset Management Inc	799,340	$1.86M	0.0%	+82.7%	0.382%
8/1/2024	Rhumbline Advisers	164,508	$0.38M	0.0%	+8.2%	0.079%
7/31/2024	Rothschild Investment LLC	22,200	$52K	0.0%	N/A	0.011%
7/29/2024	Principal Financial Group Inc.	16,836	$39K	0.0%	-45.3%	0.008%
7/26/2024	Bank of New York Mellon Corp	362,364	$0.84M	0.0%	+20.6%	0.173%
7/20/2024	Nisa Investment Advisors LLC	10,767	$25K	0.0%	+429.6%	0.005%
7/17/2024	Phoenix Wealth Advisors	13,000	$30K	0.0%	N/A	0.006%
7/12/2024	SG Americas Securities LLC	13,316	$31K	0.0%	-62.1%	0.006%
7/11/2024	Bourgeon Capital Management LLC	132,455	$0.31M	0.1%	+131.6%	0.063%
5/16/2024	California State Teachers Retirement System	107,830	$0.48M	0.0%	-4.1%	0.063%
5/16/2024	Caxton Associates LP	431,186	$1.93M	0.1%	-44.4%	0.253%
5/15/2024	Price T Rowe Associates Inc. MD	4,177,619	$18.68M	0.0%	+76.2%	2.447%
5/14/2024	EntryPoint Capital LLC	29,815	$0.13M	0.1%	-21.4%	0.017%
5/14/2024	CANADA LIFE ASSURANCE Co	17,750	$79K	0.0%	+85.1%	0.010%
5/10/2024	Vanguard Group Inc.	8,207,564	$36.69M	0.0%	-9.1%	4.808%
5/8/2024	Headlands Technologies LLC	17,396	$78K	0.0%	N/A	0.010%
5/7/2024	Susquehanna Fundamental Investments LLC	286,408	$1.28M	0.1%	N/A	0.168%
5/7/2024	SG Americas Securities LLC	35,158	$0.16M	0.0%	-34.3%	0.021%
5/1/2024	BNP Paribas Financial Markets	59,820	$0.27M	0.0%	-51.6%	0.035%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	361,913	$1.77M	0.0%	+85.1%	0.212%
4/29/2024	Principal Financial Group Inc.	30,771	$0.14M	0.0%	-11.1%	0.018%
4/29/2024	China Universal Asset Management Co. Ltd.	32,348	$0.15M	0.0%	+66.2%	0.019%
4/19/2024	Bourgeon Capital Management LLC	57,200	$0.26M	0.1%	+12.8%	0.034%
4/5/2024	Los Angeles Capital Management LLC	160,623	$0.72M	0.0%	-3.2%	0.095%
2/14/2024	Caxton Associates LP	775,093	$2.49M	0.1%	+61.4%	0.461%
2/14/2024	Pennant Investors LP	128,400	$0.41M	0.1%	N/A	0.076%
2/14/2024	Superstring Capital Management LP	222,112	$0.71M	0.5%	N/A	0.132%
2/13/2024	Affinity Asset Advisors LLC	400,000	$1.28M	0.2%	N/A	0.238%
2/12/2024	RPO LLC	14,333	$46K	0.1%	N/A	0.009%
2/9/2024	Primecap Management Co. CA	5,281,886	$16.96M	0.0%	0.0%	3.139%
2/8/2024	Mitsubishi UFJ Asset Management Co. Ltd.	221,094	$0.74M	0.0%	+20.2%	0.131%
2/7/2024	BNP Paribas Financial Markets	123,518	$0.40M	0.0%	-78.3%	0.073%
2/7/2024	Calton & Associates Inc.	21,060	$68K	0.0%	N/A	0.013%
2/6/2024	Axxcess Wealth Management LLC	10,677	$34K	0.0%	N/A	0.006%
2/6/2024	Los Angeles Capital Management LLC	165,978	$0.53M	0.0%	N/A	0.099%
2/6/2024	Swiss National Bank	214,800	$0.69M	0.0%	+11.6%	0.128%
2/5/2024	Victory Capital Management Inc.	14,283	$46K	0.0%	+23.1%	0.008%
1/31/2024	Daiwa Securities Group Inc.	32,498	$0.10M	0.0%	+116.3%	0.019%
1/30/2024	Zurcher Kantonalbank Zurich Cantonalbank	22,551	$72K	0.0%	+55.4%	0.013%
1/30/2024	Bourgeon Capital Management LLC	50,700	$0.16M	0.0%	-17.8%	0.030%
1/30/2024	Cornercap Investment Counsel Inc.	60,634	$0.20M	0.0%	N/A	0.036%
1/30/2024	Vontobel Holding Ltd.	18,000	$58K	0.0%	+28.6%	0.011%
1/26/2024	Cerity Partners LLC	517,581	$1.66M	0.0%	N/A	0.308%
1/26/2024	Aaron Wealth Advisors LLC	10,729	$34K	0.0%	N/A	0.006%
1/24/2024	Mirae Asset Global Investments Co. Ltd.	195,480	$0.63M	0.0%	-54.4%	0.116%
1/24/2024	Arizona State Retirement System	30,458	$98K	0.0%	+22.2%	0.018%
1/24/2024	China Universal Asset Management Co. Ltd.	19,467	$62K	0.0%	+353.0%	0.012%
1/18/2024	McGlone Suttner Wealth Management Inc.	8,376	$27K	0.0%	N/A	0.005%
1/12/2024	SG Americas Securities LLC	53,484	$0.17M	0.0%	N/A	0.032%
1/10/2024	Nordea Investment Management AB	740,683	$2.38M	0.0%	-3.1%	0.440%
1/8/2024	Harbor Capital Advisors Inc.	73,510	$0.24M	0.0%	+7.3%	0.044%
1/5/2024	Exchange Traded Concepts LLC	36,040	$0.12M	0.0%	+34.0%	0.021%
12/18/2023	Vanguard Group Inc.	10,587,804	$33.56M	0.0%	+41.1%	6.292%
11/24/2023	EP Wealth Advisors LLC	10,850	$34K	0.0%	N/A	0.006%
11/15/2023	Alps Advisors Inc.	123,718	$0.39M	0.0%	+15.4%	0.074%
11/14/2023	Corton Capital Inc.	12,628	$40K	0.0%	-52.5%	0.008%
11/14/2023	Caxton Associates LP	480,104	$1.52M	0.2%	+590.0%	0.285%

Data available starting January 2016

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Today's Range

Now: $2.17

$2.00

$2.17

50 Day Range

MA: $2.43

$1.84

$3.22

52 Week Range

Now: $2.17

$1.78

$5.78

Volume

2,861,783 shs

Average Volume

2,488,550 shs

Market Capitalization

$454.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Who are the company insiders with the largest holdings of Allogene Therapeutics?: Allogene Therapeutics' top insider shareholders include:
Arie Belldegrun (Director)
Geoffrey M Parker (CFO)
Veer Bhavnagri (General Counsel)
Franz B Humer (Director)
Deborah M Messemer (Director)
Stephen Mayo (Director)
Learn More about top insider investors at Allogene Therapeutics.
Who are the major institutional investors of Allogene Therapeutics?: Allogene Therapeutics' top institutional shareholders include:
FMR LLC — 14.32%
State Street Corp — 3.34%
JPMorgan Chase & Co. — 1.95%
Geode Capital Management LLC — 1.54%
Vestal Point Capital LP — 0.72%
Zacks Investment Management — 0.25%
Learn More about top institutional investors of Allogene Therapeutics stock.
Which institutional investors are selling Allogene Therapeutics stock?: During the previous quarter, ALLO stock was sold by these institutional investors:
FMR LLC
Vestal Point Capital LP
State Street Corp
Tidal Investments LLC
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
JPMorgan Chase & Co.
Cornercap Investment Counsel Inc.
MetLife Investment Management LLC
Within the previous year, company insiders that have sold Allogene Therapeutics company stock include:
Arie Belldegrun (Director)
Geoffrey M Parker (CFO)
Learn More investors selling Allogene Therapeutics stock.
Which institutional investors are buying Allogene Therapeutics stock?: During the previous quarter, ALLO stock was acquired by institutional investors including:
Zacks Investment Management
Geode Capital Management LLC
Barclays PLC
Barclays PLC
Curi RMB Capital LLC
Intech Investment Management LLC
BNP Paribas Financial Markets
SG Americas Securities LLC
Within the previous year, these company insiders have bought Allogene Therapeutics stock:
Arie Belldegrun (Director)
Geoffrey M Parker (CFO)
Learn More investors buying Allogene Therapeutics stock.

$20k in extra income?

From DTI | Ad